Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lakefront Biotherapeutics NV (Lakefront Biotherapeutics), formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. The company’s pipeline products include GLPG3667 which treats systemic lupus erythematosus and dermatomyositis; GLPG5101 for ATALANTA-1 study in relapsed and refractory B-cell malignancies; and GLPG5301 which targets PAPILIO-1 study in relapsed and refractory multiple myeloma. It provides clinical trials in the therapeutic areas including immunology and oncology. The company operates in the US, the Netherlands, France, Switzerland, China, and the UK. Lakefront Biotherapeutics is headquartered in Mechelen, Flemish Brabant, Belgium.
Headquarters
Belgium
Address
Generaal De Wittelaan L11 A3, Mechelen, 2800
Website
www.glpg.com
Telephone
32 15 342900
No of Employees
452
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LKFT (AMS)
Revenue (2024)
$1.3B
303.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
333.1%
(2024 vs 2023)
Market Cap*
$1.9B
Net Profit Margin (2024)
XYZ
7.3%
(2024 vs 2023)
* As of and is in US$
Lakefront Biotherapeutics NV premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| GLPG3667: |
| Systemic Lupus Erythematosus |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Plans/Strategy | In October, the company announced its plans to close its cell therapy business. |
| 2025 | Contracts/Agreements | In April, the company signed an agreement to sell small molecule immunology and oncology assets, including Phase 1-ready SIK3 inhibitor to Onco3R Therapeutics. |
| 2025 | Contracts/Agreements | In February, the company partnered with NecstGen to support the decentralized manufacturing of cell therapy products. |
Competitor Comparison
| Key Parameters | Lakefront Biotherapeutics NV | AstraZeneca Plc | GSK plc | Oxurion NV | Celyad Oncology SA |
|---|---|---|---|---|---|
| Headquarters | Belgium | United Kingdom | United Kingdom | Belgium | Belgium |
| City | Mechelen | Cambridge | London | Leuven | Mont-Saint-Guibert |
| State/Province | - | Cambridgeshire | England | - | - |
| No. of Employees | 452 | 96,100 | 66,841 | 26 | 1 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gino Santini | Chairman | Executive Board | 2026 | - |
| Henry Gosebruch | Director; Chief Executive Officer | Executive Board | 2025 | 53 |
| Aaron Cox | Chief Financial Officer; Executive Vice President | Senior Management | 2025 | 41 |
| Dan Grossman | Chief Strategy Officer | Senior Management | 2025 | - |
| Eric Hedrick, MD | Chief Medical Officer | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer